Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Insulin Resistance Also Mediated by White Blood Cells

By BiotechDaily International staff writers
Posted on 13 Aug 2012
Print article
Image: False-color scanning electron micrograph (SEM) of a neutrophil (Photo courtesy of UC San Diego School of Medicine).
Image: False-color scanning electron micrograph (SEM) of a neutrophil (Photo courtesy of UC San Diego School of Medicine).
Researchers have now found that neutrophils play a role in mediating the development of insulin resistance, the central characteristic of type 2 diabetes. The discovery also provides a potential new treatment target.

Using live mouse models as well as cultured liver and fat cells, a study team based at the University of California, San Diego, School of Medicine (La Jolla, CA, USA) discovered that an enzyme secreted by neutrophils called neutrophil elastase (NE) impairs insulin signaling and boosts resistance. Conversely, deletion of NE in obese mice fed a high-fat diet improved insulin sensitivity. “These results are largely unexpected. Although several immune cells have been established in the etiology of insulin resistance, the role of neutrophils in this process has remained unclear until now,” said Da Young Oh, co-author and assistant project scientist in the laboratory of study leader Jerrold M. Olefsky, MD and professor of medicine.

Chronic low-grade inflammation is an important cause of systemic insulin resistance. Neutrophils are the first immune cells to respond to tissue inflammation and can promote chronic inflammation by helping to recruit additional white blood cells - macrophages. Oh noted that neutrophils were considered to be “transient infiltrates” incapable of sustaining chronic, low-grade inflammation. “Our studies now suggest neutrophils possess powerful immune modulatory effects,” Oh said. Specifically, neutrophils use NE to activate a signaling pathway that triggers macrophages to secrete proinflammatory cytokines. NE degrades IRS1, a key protein in the insulin-signaling pathway in both liver and fat cells. The scientists noted that although NE has been shown to degrade this protein in lung cancer cells, the effect on insulin target tissues such as liver and adipose is striking.

The insulin-mediating role of neutrophils makes them a new target for developing treatments of insulin resistance in particular and diabetes in general. “One could, in theory, take an NE activity inhibitory approach to reverse or improve insulin resistance,” Oh said, noting that NE inhibiting drugs are already used for treatment of emphysema in Japan and are being tested in the United States for both emphysema and type 1 diabetes.

The findings have been reported in the August 5, 2012, advance online edition of the journal Nature Medicine.

Related Links:

University of California, San Diego, School of Medicine



Print article

Channels

Biochemistry

view channel
Image: A space-filling model of the anticonvulsant drug carbamazepine (Photo courtesy of Wikimedia Commons).

Wastewater May Contaminate Crops with Potentially Dangerous Pharmaceuticals

Reclaimed wastewater used to irrigate crops is contaminated with pharmaceutical residues that can be detected in the urine of those who consumed such produce. Investigators at the Hebrew University... Read more

Lab Technologies

view channel
Image: A three-dimensional printer adapted for stem cell production (Photo courtesy of Nano Dimension).

Israeli Developers Demonstrate Prototype Three-Dimensional Bioprinter

Two Israeli companies have combined efforts in the development of three-dimensional printer technology for the production of stem cells. The three-dimensional print electronics developer Nano Dimension... Read more

Business

view channel

Acquisition to Boost Development of Drugs for Neurogenic Conditions

According to a recent announcement, a privately held biotechnology/drug development company is to be acquired by one of the major pharmaceutical manufacturers. The drug manufacturer Merck & Co. (Kenilworth, NJ, USA) has agreed to pay 500 million USD up front for Afferent Pharmaceuticals (San Mateo, CA, USA) and up... Read more
Copyright © 2000-2016 Globetech Media. All rights reserved.